ARG1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, in high-risk CML patients, levels of ARG1-expressing PD-L1 + MDSCs increased, as did PD-1 expression on T cells, and MDSC levels decreased to normal after therapy with imatinib [63].